Kaiser Foundation Health Plan Inc v. Merck & Company Inc. et al
Filing
58
ORDER GRANTING 57 STIPULATION Regarding Briefing Schedule. Motions due by 4/2/2024; Responses due by 4/30/2024; and Replies due by 5/17/2024. Signed by Judge Haywood S. Gilliam, Jr. on 3/27/2024. (ndr, COURT STAFF) (Filed on 3/27/2024)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
GIBSON, DUNN & CRUTCHER LLP
Samuel G. Liversidge, SBN 180578
SLiversidge@gibsondunn.com
Sarah M. Kushner, SBN 320077
SMKushner@gibsondunn.com
333 South Grand Avenue
Los Angeles, California 90071
Telephone:
213.229.7000
Facsimile:
213.229.7520
S. Christopher Whittaker, SBN 283518
CWhittaker@gibsondunn.com
Courtney L. Spears, SBN 329521
CSpears@gibsondunn.com
3161 Michelson Drive
Irvine, California 92612
Telephone:
949.451.3800
Facsimile:
949.451.4220
Attorneys for Defendants
Merck & Company, Inc., Merck Sharp & Dohme LLC (f/k/a Merck
Sharp & Dohme Corporation), MSP Singapore Company LLC,
Schering-Plough Corporation, and Schering Corporation
[Additional Counsel on Signature Page]
15
IN THE UNITED STATES DISTRICT COURT
16
FOR THE NORTHERN DISTRICT OF CALIFORNIA
17
OAKLAND DIVISION
18
19
20
21
KAISER FOUNDATION HEALTH PLAN,
INC.,
Plaintiff,
v.
25
MERCK & COMPANY, INC.; MERCK SHARP
& DOHME CORPORATION; SCHERINGPLOUGH CORPORATION; SCHERING
CORPORATION; MSP SINGAPORE
COMPANY LLC; GLENMARK
PHARMACEUTICALS LTD.; AND
GLENMARK PHARMACEUTICALS INC.,
USA,
26
Defendants.
22
23
24
CASE NO. 4:21-cv-05497-HSG
STIPULATION AND ORDER
REGARDING BRIEFING
SCHEDULE
27
28
Gibson, Dunn &
Crutcher LLP
STIPULATION AND ORDER REGARDING BRIEFING SCHEDULE
CASE NO. 4:21-CV-05497-HSG
1
Pursuant to Civil Local Rule 7-12, Merck & Company, Inc., Merck Sharp & Dohme LLC (f/k/a
2
Merck Sharp & Dohme Corporation), MSP Singapore Co. LLC, Schering-Plough Corporation, and
3
Schering Corporation (“Merck”), and Glenmark Pharmaceuticals Inc., USA and Glenmark
4
Pharmaceuticals Ltd. (“Glenmark” and together with Merck, “Defendants”), along with Plaintiff Kaiser
5
Health Plan Inc., by and through their undersigned counsel of record, hereby stipulate as follows:
6
WHEREAS, this action was transferred to the Eastern District of Virginia and consolidated as
7
part of In re Zetia (Ezetimbe) Antitrust Litigation, 2:18-md-02836-RBS-DEM (E.D. Va.) (the “Zetia
8
MDL”) on August 4, 2021;
9
WHEREAS, Plaintiff filed an amended complaint in the Zetia MDL on February 9, 2022;
10
WHEREAS, Defendants filed a motion to dismiss the amended complaint in the Zetia MDL on
11
March 2, 2022, which motion was fully briefed but not decided prior to the action being remanded back
12
to this Court;
13
WHEREAS, the MDL Panel remanded the action back to this Court on December 12, 2023;
14
WHEREAS, the parties believe that it is appropriate to permit Defendants to file a new motion
15
to dismiss in this Court because the prior motion addressed claims asserted by other plaintiffs in cases
16
not before this Court, the law cited in the parties’ briefing was primarily based on Fourth Circuit
17
precedent rather than Ninth Circuit precedent, and the briefing assumed a familiarity with the facts of
18
this case because it was submitted to a court that had presided over the matter for several years;
19
20
21
22
23
24
WHEREAS, the Court held a telephonic initial case management conference on February 27,
2024;
WHEREAS, the Court directed the parties to meet and confer and file a stipulation and proposed
order setting a motion to dismiss briefing schedule by March 5, 2024 (Dkt. 56);
WHEREAS, the parties have conferred and agreed to a schedule for briefing and page limits
for Defendants’ anticipated motion to dismiss;
25
NOW, THEREFORE, Plaintiff and Defendants have agreed to, and respectively submit for
26
approval by the Court, the following schedule and page limits for Defendants’ Motion to Dismiss:
27
28
Gibson, Dunn &
Crutcher LLP
1. By March 8, 2024, Plaintiff will file on the docket in this action the amended complaint it filed
in the Zetia MDL on February 9, 2022.
2
STIPULATION AND ORDER REGARDING BRIEFING SCHEDULE
CASE NO. 4:21-CV-05497-HSG
1
2
3
4
5
2. Defendants will jointly file a Motion to Dismiss by April 2, 2024, not to exceed 35 pages of
text in length.
3. Plaintiff will file an opposition to the Motion to Dismiss by April 30, 2024, not to exceed 35
pages of text in length.
4. Defendants will jointly file a reply to the opposition to the Motion to Dismiss by May 17, 2024,
6
not to exceed 25 pages of text in length.
7
IT IS SO STIPULATED.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Gibson, Dunn &
Crutcher LLP
3
STIPULATION AND ORDER REGARDING BRIEFING SCHEDULE
CASE NO. 4:21-CV-05497-HSG
1
DATED: March 5, 2024
Respectfully submitted,
2
/s/ Samuel G. Liversidge____________
Samuel G. Liversidge, SBN 180578
Sarah M. Kushner, SBN 320077
GIBSON DUNN & CRUTCHER LLP
333 South Grand Avenue
Los Angeles, CA 90071
(213) 229-7000
SLiversidge@gibsondunn.com
SMKushner@gibsondunn.com
3
4
5
6
7
S. Christopher Whittaker, SBN 283518
Courtney L. Spears, SBN 329521
GIBSON DUNN & CRUTCHER LLP
3161 Michelson Drive
Irvine, California 92612-4412
(949) 451-3800
cwhittaker@gibsondunn.com
cspears@gibsondunn.com
8
9
10
11
12
Attorneys for Defendants Merck & Company, Inc.,
Merck Sharp & Dohme LLC (f/k/a Merck Sharp &
Dohme Corporation), MSP Singapore Company
LLC, Schering-Plough Corporation, and Schering
Corporation
13
14
15
/s/ Devora W. Allon_____________
Devora W. Allon, P.C. (pro hac vice)
Kevin M. Neylan, Jr. (pro hac vice)
Patrick J. Gallagher (pro hac vice)
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, NY 10022
(212) 446-4800
devora.allon@kirkland.com
kevin.neylan@kirkland.com
patrick.j.gallagher@kirkland.com
16
17
18
19
20
21
Michael Shipley, SBN 233674
KIRKLAND & ELLIS LLP
555 South Flower Street
Los Angeles, CA 90071
(213) 680-8400
michael.shipley@kirkland.com
22
23
24
25
James R P Hileman (pro hac vice)
KIRKLAND & ELLIS LLP
300 North LaSalle
Chicago, IL 60654
(312) 862-2000
jhileman@kirkland.com
26
27
28
Gibson, Dunn &
Crutcher LLP
4
STIPULATION AND ORDER REGARDING BRIEFING SCHEDULE
CASE NO. 4:21-CV-05497-HSG
1
Attorneys for Defendants Glenmark
Pharmaceuticals Inc., USA and Glenmark
Pharmaceuticals Ltd.
2
3
4
/s/ Daniel A. Sasse____________
Daniel A. Sasse, SBN 236234
Tiffanie L. McDowell, SBN 288946
CROWELL & MORING LLP
3 Park Plaza, 20th Floor,
Irvine, CA 92614
Telephone: 949.263.8400
dsasse@crowell.com
tmcdowell@crowell.com
5
6
7
8
9
Kent A. Gardiner (pro hac vice)
Mark M. Supko (pro hac vice)
CROWELL & MORING LLP
1001 Pennsylvania Avenue, NW
Washington, DC 20004
Telephone: 202.624.2500
vgaluzzo@crowell.com
msupko@crowell.com
10
11
12
13
Nicholas Dowd (pro hac vice)
CROWELL & MORING LLP
1601 Wewatta Street
Suite 815
Denver, CO 80202
Telephone: 720-322-4443
ndowd@crowell.com
14
15
16
17
Attorneys for Plaintiff Kaiser Health Plan Inc.
18
19
20
21
22
23
24
25
26
27
28
Gibson, Dunn &
Crutcher LLP
5
STIPULATION AND ORDER REGARDING BRIEFING SCHEDULE
CASE NO. 4:21-CV-05497-HSG
1
ECF ATTESTATION
2
Pursuant to Civil Local Rule 5-1(h)(3), I attest that the concurrence in the filing of this
3
4
5
document has been obtained from all other signatories.
Dated: March 5, 2024
/s/ Samuel G. Liversidge____________
Samuel G. Liversidge
6
7
* * * * *
8
ORDER
9
10
11
PURSUANT TO STIPULATION, IT IS SO ORDERED.
Dated: 3/27/2024
______________________________
Hon. Haywood S. Gilliam, Jr.
United States District Judge
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Gibson, Dunn &
Crutcher LLP
6
STIPULATION AND ORDER REGARDING BRIEFING SCHEDULE
CASE NO. 4:21-CV-05497-HSG
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?